Overview

Zhibitai Capsules for the Treatment of Primary Hyperlipidemia

Status:
NOT_YET_RECRUITING
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
Exploring the benefit risk ratio of increase in dosage of Zhibitai capsules (2 capsules at a time, 2 times a day) compared to the original dosage (1 capsule at a time, 1 day)
Phase:
PHASE2
Details
Lead Sponsor:
Chengdu Diao Jiuhong Pharmaceutical Factory
Treatments:
zhibitai